Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ReJoin (AbelZeta)
- Development stage
- Unknown
- Lead developer
- AbelZeta, Inc.
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
ReJoin is an autologous stem cell therapy developed by AbelZeta (formerly Cellular Biomedicine Group) for the treatment of knee osteoarthritis and articular cartilage defects. The therapy consists of autologous adipose-derived mesenchymal progenitor cells (haMSCs) harvested from the patient's own adipose tissue. Following isolation and expansion, these cells are administered via intra-articular injection into the knee joint. ReJoin is designed to promote the repair of damaged articular cartilage and reduce synovial inflammation, thereby improving joint function and alleviating pain in patients with degenerative joint disease.
- Brand names
- ReJoin
- Other names
- Autologous adipose-derived mesenchymal progenitor cellshaMSCsAutologous human adipose-derived mesenchymal stem cells
Beyond the preview
Go deeper on ReJoin (AbelZeta).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReJoin (AbelZeta).